8:50 am Chair’s Opening Remarks

  • Thomas Tedder Alter E. Geller Professor for Research in Immunology Departments of Immunology & Pediatrics, Duke University Medical Centre
  • Aaron Winkler Immune Tolerance Lead, Inflammation & Immunology, Pfizer

Harnessing Autoantibody Signatures and Mapping Out the B&T Cell-Mediated Autoimmune Disease Landscape

9:00 am The Human Antigenome: Autoantibody Signatures Identify Molecularly Distinct Lupus and MS Cohorts

  • Thomas Tedder Alter E. Geller Professor for Research in Immunology Departments of Immunology & Pediatrics, Duke University Medical Centre

Synopsis

  • Learn how all individuals make autoantibodies to a complex array of 300-1,000 autoantigens that are durable and unique to that individual
  • Explore how Lupus patients can be divided into at least four cohorts based on unique autoantigen patterns, with some autoantigens shared among cohorts
  • Discover unique autoantigens shared among disease cohorts that may provide insights into mechanisms of disease and treatments

9:30 am Systemic vs. Organ-Specific Autoimmune Disease: Unique Challenges & Opportunities

Synopsis

  • Overview of systemic vs. organ-specific autoimmunity using SLE and stage 2 T1D as examples, relating to “mainstream” vs. rare autoimmune disease states
  • Central and peripheral tolerance mechanisms of these diseases
  • Exploiting the disease process – successes and remaining challenges

10:00 am Panel Discussion:Mapping the Therapeutic Target Landscape for B-Cell Mediated Autoimmune Disease & T-Cell Dependent Autoantibody Responses

  • Thomas Tedder Alter E. Geller Professor for Research in Immunology Departments of Immunology & Pediatrics, Duke University Medical Centre
  • Robert Axtell Associate Member, Oklahoma Medical Research Foundation

Synopsis

  • Assessing the depletion of B-cells with anti-CD20 monoclonal antibodies
  • Exploring how to best target CD8 T suppressor cells
  • Discussing the various autoantigen specific B cell depleting and modulating therapies (CAART, BTK inhibitors, anti-CD20), targeting T-cell co-stimulatory pathways (CD40/CD40L, CD28/CTLA-4, OX40, ICOS, PD-1), and subduing autoantibody (FcRn inhibitors) approaches

10:30 am
Speed Networking & Morning Break

Synopsis

This session is the ideal opportunity to network and forge meaningful business relationships with many of the brightest minds working in the B & T cell field, face to-face for the first time

Highlighting T-Cell Interactions & Nanoparticle-Based Interactions for Immune Tolerance

11:30 am PLG Nanoparticle-Based Antigen Delivery for The Tolerogenic Treatment of Autoreactive T & B Cell Responses in a Mouse Model of Neuromyelitis Optica (NMO)

  • Stephen Miller Professor of Microbiology- Immunology, Northwestern University

Synopsis

  • Review the mechanisms of PLG nanoparticle-induced tolerance and its translational potential in a Phase 1/2a clinical trial in celiac disease
  • Describe the requirements for induction of a new mouse model of NMO
  • Decipher the efficacy of tolerance using PLG nanoparticle delivery of aquaporin-4 (AQP4) for prevention and treatment of NMO

12:00 pm Session Reserved for Adaptive Biotechnologies

12:30 pm A Novel NanoDisc Platform for Induction of Antigen-Specific Immune Tolerance

  • James Moon Co-Founder & Chief Scientific Officer, Professor of Pharmaceutical Sciences, EVOQ Therapeutics, University of Michigan

Synopsis

  • Examine how subcutaneous administration of NanoDisc targets multiple lymphoid tissues and immune system organs
  • Discover how NanoDisc carrying autoantigens induce antigen-specific T-Regs and Tr1 cells, while reducing autoreactive IgG response
  • Learn how NanoDisc therapy exerts robust efficacy in preclinical models of Multiple Sclerosis and Type 1 Diabetes

1:00 pm Manipulation of Apoptosis for Induction of Antigen-specific T-regs to Treat Autoimmunity

  • Wanjun Chen Principle National Investigator, Nation Institute of Health

Synopsis

  • Inducing specific immunotherapy to autoimmunity without compromising overall immune responses
  • Explore how to induce autoantigen-specific Tregs in animals, and ultimately in patients with established autoimmune disease
  • Learn about the manipulation of the apoptosis of immune cells with antibodies and nanoparticles together with administration of autoantigens

1:30 pm
Lunch & Networking

Comparing the Efficacy of Small Molecule Targeting on Signaling Pathways & their Impact on Autoimmune Diseases

2:30 pm Investigating GB7208: An Oral, CNS-Penetrant, Irreversible BTK inhibitor for the Treatment of Neuroinflammatory Diseases

Synopsis

  • Learn how BTK inhibitors are actively being explored in inflammatory diseases
  • Discover how they are characterized by modest selectivity and/or limited central nervous system (CNS) penetrance
  • Assess GB7208, an orally available, selective, irreversible small molecule BTK inhibitor which has been selected based on its potency, specificity, and high brain penetrance in preclinical models

3:00 pm Exploring NX-5948: A CNS Penetrant Selective Degrader of BTK that Significantly Reduces Inflammation in Mouse Models of Autoimmune Disease

  • Ryan Rountree Sr. Director, Preclinical Pharmacology, Nurix Therapeutics

Synopsis

  • Uncover NX-5948, a highly potent, CNS penetrant, targeted protein degrader of BTK in Phase 1 clinical development for B cell malignancies
  • Evaluate how daily oral administration of NX-5948 provides efficacy in multiple preclinical models of autoimmune disease
  • Learn how NX-5948 preclinical data supports further exploration of NX-5948 to treat autoimmune diseases

3:30 pm
Scientific Poster Session & Afternoon Break

Translating Therapeutics into the Clinic: Autoimmune Disease Biomarkers & Clinical Trial Considerations

4:00 pm Identifying the Challenges & Opportunities with Type 1 Diabetes Biomarkers

  • Simi Ahmed Senior Vice President, Strategic Partnerships, New York Stem Cell Foundation

Synopsis

  • Reviewing the current state of T1D biomarkers
  • Exploring the advances and challenges that the field is facing
  • Drafting a proposed path to implementable biomarkers

4:30 pm Biomarkers & Environmental Factors that Can Predict Prognosis & Treatment Response in Multiple Sclerosis

  • Robert Axtell Associate Member, Oklahoma Medical Research Foundation

Synopsis

  • Developing precision medicine approaches for hard-to-treat autoimmune patients
  • What is the immune cell phenotype of the individual patient?
  • Environmental factors and their influence on MS patients

5:00 pm Chair’s Closing Remarks

  • Thomas Tedder Alter E. Geller Professor for Research in Immunology Departments of Immunology & Pediatrics, Duke University Medical Centre
  • Aaron Winkler Immune Tolerance Lead, Inflammation & Immunology, Pfizer